Advertisement

Medical device giant Boston Scientific asks the FCC for permission to continue using restricted radio frequencies as the company attempts to complete enrollment in its ongoing MultiSense CRT-D monitoring study.

Boston Scientific logo

Boston Scientific (NYSE:BSX) needs some extra time to complete its MultiSense CRM monitoring study, the company told the Federal Communications Commission in requesting an extended waiver to access a restricted radiofrequency band.

The MultiSense trial, launched in 2010, combines the multi-sensor Cognis model cardiac resynchronization therapy defibrillator with Boston Scientific's Latitude patient management system, which wirelessly transmits data from the CRT-D to the patient's physician.

Advertisement
Advertisement